Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma

Hari K Narayan,1,2 Mary E Putt,3 Nikitha Kosaraju,4 Alejandro Paz,4 Shivani Bhatt,5 Theodore Plappert,6 Laura Mercer-Rosa,7 Saro H Armenian,8 Ami V Desai,9 Richard B Womer,5,10 Bonnie Ky11

ABSTRACT:
Objective We sought to determine how sex and dexrazoxane therapy influence cardiac remodelling in children with sarcoma receiving high-dose doxorubicin.

Methods In a retrospective cohort of 85 children with sarcoma receiving high-dose doxorubicin, echocardiography measures prior to, early after (within 6 months of doxorubicin completion) and 1–2 years after doxorubicin completion were quantified. At each follow-up visit, multivariable, propensity-adjusted linear regression models evaluated dexrazoxane’s effects on changes in left ventricular (LV) shortening fraction (SF), structure, strain and wall stress for subgroups divided by sex. Likelihood ratio tests assessed the interaction between sex and dexrazoxane in determining these changes.

Results Early after doxorubicin completion, males not treated with dexrazoxane (n = 15) developed increased cavity size and diminished circumferential strain; females (n = 8) developed diminished SF and strain indices, and increased cavity size and wall stress. With dexrazoxane, males (n = 33) demonstrated less deterioration in circumferential strain by 3.4% (95% CI 0.1 to 6.8), and females (n = 29) demonstrated less reduction in SF by 5.7% (95% CI 2.1 to 9.3), and had mitigation of increases in cavity size and wall stress. In interaction analyses, females had greater protection with dexrazoxane with regard to SF (p = 0.019) and cavity size in diastole (p = 0.002) and systole (p = 0.001). These findings largely persisted 1–2 years after doxorubicin therapy.

Conclusions Early, sustained alterations in LV structure and function occur in children with sarcoma after high-dose doxorubicin, with adverse changes and protective effects of dexrazoxane more pronounced in females as compared with males. Dexrazoxane may have sex-specific cardioprotective effects.

INTRODUCTION
Anthracyclines are commonly used in the treatment of childhood cancers, but they confer a substantial risk of dose-dependent cardiotoxicity and associated cardiovascular morbidity and mortality.1 2 Children with sarcoma, a highly aggressive malignant solid tumour, are often treated with some of the highest cumulative anthracycline doses—on the order of 375–450 mg/m2 of doxorubicin—and are thus particularly vulnerable to cardiac injury.3 4 Anthracycline-treated children may develop deterioration of left ventricular (LV) shortening fraction (SF), a surrogate of global LV systolic function, in addition to adverse changes in LV structure, contractility and afterload, each of which contribute to global systolic function.5 6

Dexrazoxane, an intracellular iron chelator, inhibits anthracycline-induced free-radical injury and topoisomerase II beta mediated DNA damage, and may be protective against these cardiotoxic effects.5 10 Female children may be particularly vulnerable to anthracycline cardiotoxicity,11 12 and may preferentially benefit from

Key questions
What is already known about this subject?
► Anthracycline chemotherapy can cause dose-dependent cardiotoxicity and children with sarcoma are treated with some of the highest doses of these agents.

What does this study add?
► In this retrospective longitudinal cohort study, we performed detailed characterisation of echocardiography measures of cardiac structure and function before, early after and 1–2 years after high-dose anthracycline therapy in children with sarcoma. Female children were particularly susceptible to adverse changes in cardiac structure and function, and derived preferential benefit from dexrazoxane, a cardioprotectant given concurrently with anthracycline therapy. Early adverse changes in strain measures were associated with later declines in shortening fraction.

How might this impact on clinical practice?
► With further research, sex may be considered as a factor in the decision-making process of whether to use dexrazoxane. This study, in conjunction with published data in adults, provides support for the use of echocardiographic strain indices in the early monitoring of anthracycline-exposed children.

Additional material is published online only. To view these files, please visit the journal online (http://dx.doi.org/10.1136/openhrt-2019-001025).


Received 1 February 2019
Revised 27 March 2019
Accepted 26 April 2019
 dexrazoxane. However, prior studies have focused primarily on lower anthracycline doses than sarcoma patients often receive, and important questions remain. The early and sustained effects of high-dose anthracyclines in paediatric sarcoma patients on measures of cardiovascular function and remodelling, including strain, and how these effects differ by sex and dexrazoxane therapy exposure, remain incompletely understood. A more robust understanding of these effects could help inform monitoring and treatment strategies.

Our objective was to characterise the effects of sex and dexrazoxane exposure in influencing early changes in LV function and remodelling after high-dose doxorubicin therapy for paediatric sarcoma. To accomplish this objective, we performed a retrospective, longitudinal cohort study examining detailed quantitative echocardiography assessments over standardised follow-up time intervals.

### MATERIALS AND METHODS

#### Study population

Via an institutional cancer database search, a retrospective cohort of sarcoma patients at the Children’s Hospital of Philadelphia (Philadelphia, PA, USA) was identified who met the following eligibility criteria: (1) sarcoma diagnosis (Ewing sarcoma, osteosarcoma, rhabdomyosarcoma...
Heart failure and cardiomyopathies

Table 2  Echocardiography measures at baseline according to dexrazoxane exposure

<table>
<thead>
<tr>
<th>Echocardiography Measure</th>
<th>No Dexrazoxane* (n=23)</th>
<th>Dexrazoxane* (n=62)</th>
<th>P†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shortening Fraction, %</td>
<td>33.0 (4.2)</td>
<td>30.1 (5.5)</td>
<td>0.025</td>
</tr>
<tr>
<td>LVDD, cm/BSA0.45</td>
<td>3.8 (0.4)</td>
<td>3.9 (0.3)</td>
<td>0.1</td>
</tr>
<tr>
<td>LVDS, cm/BSA0.45</td>
<td>2.5 (0.3)</td>
<td>2.7 (0.2)</td>
<td>0.002</td>
</tr>
<tr>
<td>Posterior Wall Thickness, cm/BSA0.40</td>
<td>0.6 (0.1)</td>
<td>0.6 (0.1)</td>
<td>0.5</td>
</tr>
<tr>
<td>LV Mass, gr/BSA1.25</td>
<td>63 (18)</td>
<td>65 (13)</td>
<td>0.53</td>
</tr>
<tr>
<td>Relative Wall Thickness</td>
<td>0.33 (0.07)</td>
<td>0.31 (0.06)</td>
<td>0.19</td>
</tr>
<tr>
<td>Circumferential Strain, %</td>
<td>−25.1 (3.3)</td>
<td>−23.0 (4.1)</td>
<td>0.045</td>
</tr>
<tr>
<td>Radial Strain, %</td>
<td>39.6 (18.0)</td>
<td>41.1 (25.9)</td>
<td>0.82</td>
</tr>
<tr>
<td>Meridional ESS, 10³ dynes/cm²</td>
<td>83 (17)</td>
<td>98 (30)</td>
<td>0.031</td>
</tr>
<tr>
<td>Circumferential ESS, 10³ dynes/cm²</td>
<td>136 (20)</td>
<td>149 (27)</td>
<td>0.064</td>
</tr>
</tbody>
</table>

*P-values from two-sided two-sample t-tests comparing no dexrazoxane to dexrazoxane.
†Mean (SD).
BSA, body surface area; ESS, end-systolic stress; LV, left ventricular; LVDD, LV inner dimension in diastole; LVDS, LV inner dimension in systole.

or non-rhabdomyosarcoma soft tissue sarcoma) made between 1 January 2006 and 1 February 2015; (2) treatment including at least 150 mg/m² of doxorubicin and completely administered at the Children’s Hospital of Philadelphia and (3) archived echocardiographic images at baseline before doxorubicin initiation and after completion. Clinical data through 1 February 2016 were extracted through a comprehensive chart review.

Subjects were treated with standard chemotherapy regimens as determined by the treating clinician. Regimens typically included a total of 375–450 mg/m² of doxorubicin given over a period of approximately 6 months. Within each cycle, doxorubicin was administered either as (1) a 75 mg/m² continuous infusion over 48 hours; or (2) two 37.5 mg/m² doxorubicin boluses given 24 hours apart, each preceded by 375 mg/m² of dexrazoxane (10:1 dexrazoxane:doxorubicin dosage ratio). Prior to August 2009, the majority of subjects were given continuous infusion doxorubicin without dexrazoxane; at the treating provider’s discretion, some subjects received bolus doxorubicin with dexrazoxane during this time period. As per a change in institutional protocol, beginning in August 2009, all subjects were given bolus doxorubicin with dexrazoxane. Apart from dexrazoxane, there were no significant changes in treatment regimens over the study period. Given that 30% of subjects in the earlier era and 73% of the overall cohort received dexrazoxane, there was an opportunity to evaluate the effects of this drug. The local Institutional Review Board approved this study.

Echocardiography

Clinical echocardiograms were routinely performed to monitor for cardiotoxicity. Archived echocardiography images (30 frames per second, using a similar approach to prior studies) from three time points were obtained: prior to doxorubicin initiation (T₀); early after (within 6 months of) doxorubicin completion (T₁) and 1–2 years after doxorubicin completion (T₂; figure 1). Echocardiograms were quantitated at the University of Pennsylvania Center for Quantitative Echocardiography (Philadelphia) by a single observer, blinded to subject characteristics. Quantitation details are provided in the online supplementary Methods.

Cavity size (LV inner dimension in diastole (LVDD), LV inner dimension in systole (LVDS)), myocardial wall size (posterior wall thickness and LV mass) and the ratio of wall thickness to cavity diameter (relative wall thickness) were quantitated to characterise structural remodelling. To provide further insight into systolic function, peak systolic strain was determined in the circumferential and radial dimensions from the parasternal short axis views. Wall stress, an index of afterload, was assessed via measures of meridional and circumferential end-systolic stress (ESS). Finally, SF, an assessment of global systolic function, was calculated from LVDD and LVDS. Longitudinal strain and ejection fraction were not analysed due to limitations in image quality in the apical views.

In order to account for normal growth, LVDD, LVDS, posterior wall thickness and LV mass were divided by body surface area (BSA) to the power of 0.45, 0.45, 0.40 and 1.25 respectively, adjustments that were derived from a prior study of normal children. In this report, we characterise the BSA-adjusted values of these parameters.

Statistical methods

Standard descriptive statistics characterised the study population at baseline. Two sample t-tests or Wilcoxon rank sum tests (for continuous variables) and Pearson’s χ² tests (for categorical variables) were used to test for baseline differences by dexrazoxane exposure status. We either stratified by or adjusted for sex and dexrazoxane exposure in all analyses, anticipating differences between these groups based on previously published findings.
Figure 2  Changes in shortening fraction over time. In subgroups divided by sex and dexrazoxane exposure, LOESS smoothed curves with 95% CIs depict changes in shortening fraction over time.

Figure 3  Changes in structure, strain and wall stress over time. In subgroups divided by sex and dexrazoxane exposure, LOESS smoothed curves with 95% CIs depict changes in: A-left ventricular (LV) inner dimension in diastole (LVIDD); B-LV inner dimension in systole (LVIDS); C-posterior wall thickness (PWT); D-LV mass; E-relative wall thickness; F-circumferential strain; G-radial strain; H-meridional end-systolic stress (ESS); I-circumferential ESS.
Table 3  Effect of dexrazoxane on changes in echocardiography measures from baseline early after doxorubicin chemotherapy (T1) according to sex

<table>
<thead>
<tr>
<th>Measure</th>
<th>Males (n=48)</th>
<th>Females (n=37)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Effect of dexrazoxane on change at T1 (95% CI)*</td>
<td>Effect of dexrazoxane on change at T1 (95% CI)*</td>
</tr>
<tr>
<td>Shortening fraction (%)</td>
<td>0.5 (−2.4 to 3.4)</td>
<td>5.7 (2.1 to 9.3)</td>
</tr>
<tr>
<td>LVDD (cm/BSA)</td>
<td>0.1 (−0.1 to 0.3)</td>
<td>−0.4 (−0.7 to −0.1)</td>
</tr>
<tr>
<td>LVDS (cm/BSA)</td>
<td>−0.03 (−0.2 to 0.1)</td>
<td>−0.6 (−0.8 to −0.4)</td>
</tr>
<tr>
<td>Posterior wall thickness (cm/BSA)</td>
<td>0.02 (−0.03 to 0.08)</td>
<td>0.04 (−0.03 to 0.10)</td>
</tr>
<tr>
<td>LV mass (g/BSA)</td>
<td>4.0 (−5.2 to 13.2)</td>
<td>−7.1 (−18.8 to 4.6)</td>
</tr>
<tr>
<td>Relative wall thickness (%)</td>
<td>0.00 (−0.03 to 0.03)</td>
<td>0.05 (0.01 to 0.08)</td>
</tr>
<tr>
<td>Circumferential strain (%)§</td>
<td>−3.4 (−6.8 to 0.0)</td>
<td>−0.6 (−5.0 to 3.8)</td>
</tr>
<tr>
<td>Radial strain (%)</td>
<td>4.6 (−8.2 to 17.5)</td>
<td>9.9 (−6.9 to 26.8)</td>
</tr>
<tr>
<td>Meridional ESS (10^5) dynes/cm²</td>
<td>−7.9 (−24.0 to 8.2)</td>
<td>−29.2 (−51.1 to −7.2)</td>
</tr>
<tr>
<td>Circumferential ESS (10^3 dynes/cm²)</td>
<td>−7.1 (−23.6 to 9.3)</td>
<td>−18.9 (−41.6 to 3.9)</td>
</tr>
</tbody>
</table>

*Difference in the mean change at T1, (within 6 months of doxorubicin therapy completion) between subjects who were exposed and not exposed to dexrazoxane, derived from propensity-adjusted multivariable linear regression.
†P<0.05 for the comparison of mean changes by dexrazoxane exposure, performed separately for males and females.
‡P-values for the interaction between sex and dexrazoxane.
§Increases reflect deterioration of circumferential strain.
LVDD, LV inner dimension in diastole; LVDS, LV inner dimension in systole; BSA, body surface area; ESS, end-systolic stress; LV, left ventricular; LVDD, LV inner dimension in diastole.

Locally estimated scatterplot smoothing (LOESS) smoothed curves were derived from unadjusted changes in each measure over time; these curves did not account for within subject correlation. Multivariable linear regression modelled the changes in echocardiography measures separately at T1 and T2, to assess for differences by sex and dexrazoxane exposure status. Sex, dexrazoxane exposure, and the interaction of sex and dexrazoxane exposure were included in each model. These models were adjusted for the propensity to receive dexrazoxane in addition to other prespecified potential confounders: age, race and baseline echocardiographic measure. We created a propensity score for the receipt of dexrazoxane using the subcohort of subjects who were treated before dexrazoxane use was universal.19 We used logistic regression to determine a propensity for the receipt of dexrazoxane, and applied this propensity to the overall cohort. The goal here was to adjust for characteristics of the population that influenced receipt of dexrazoxane during the period prior to universal treatment. Predictors in the propensity score model were baseline SF, age, sex, race, body mass index, BSA, sarcoma type, cumulative doxorubicin dose and chest radiation exposure.

Using these models, Wald tests compared mean changes by dexrazoxane exposure according to sex. To assess for effect modification of dexrazoxane’s effects by sex, likelihood ratio tests compared full models described above (with the interaction term between sex and dexrazoxane) to reduced models (without the interaction term). Adjustment for multiple comparisons was performed on interaction p-values using a false discovery rate of 5%.

We characterised the temporal relationships between measures at T1 with changes at T2. Paired t-tests determined whether there were differences in mean values of measures at T1 and T2. In order to identify early markers of disease, we used multivariable linear regression to determine the associations of changes in each echocardiographic parameter early postdoxorubicin completion (at T1) with the change in SF 1–2 years postdoxorubicin completion (at T2). These models were adjusted for baseline SF, baseline echocardiographic parameter of interest, age, race, sex, dexrazoxane exposure, and the interaction between sex and dexrazoxane exposure.

All tests were two-sided, the type I error rate was set at 0.05, and CIs were at the 95% level throughout. Statistical
analyses were performed using STATA V.13.1 (StataCorp). Graphics were generated using the ggplot2 package in R V.3.3.3 (R Foundation for Statistical Computing, Vienna, Austria).20

RESULTS

Study population
Eighty-five subjects were eligible for the study, including 37 females (44%) and 62 dexrazoxane recipients (73%; table 1). The average age at baseline was 13.0 years. Overall, 40% had Ewing sarcoma, 35% had osteosarcoma, 8% rhabdomyosarcoma and 17% non-rhabdomyosarcoma soft tissue sarcoma. On initial presentation, 74% of tumours were isolated to a single location, 13% were metastatic to the lungs and 13% were widely metastatic. The median cumulative dose of doxorubicin therapy was 375 mg/m² (IQR 375, 450). Seven subjects received chest radiation, five to primary thoracic sites and two to metastatic lung lesions. Characteristics of subjects who did and did not receive dexrazoxane were similar.

Clinical outcomes
Nine subjects suffered from cardiac events related to cancer therapy: five developed symptomatic heart failure, three had dose reductions or omissions due to LV dysfunction on echocardiography and one had a significant arrhythmia (medically aborted torsades de pointes). Of these nine subjects, two were male (one treated with and one not treated with dexrazoxane) and seven were female (three treated with and four not treated with dexrazoxane). Four of the five subjects who developed heart failure were treated with afterload reduction medications. Deaths occurred in two of these five subjects with heart failure. One developed a pregnancy while in chronic heart failure with no evidence of cancer; she was lost to follow-up and the circumstances of death were not available (death occurred 4.2 years after diagnosis). Another death was related to care withdrawal in the setting of terminal cancer, sepsis and multiorgan failure (1.6 years after diagnosis). Thirty-two deaths occurred over the duration of available follow-up, at a median of 2.1 years; all other deaths were cancer-related. Overall survival estimated by the Kaplan Meier method at 1, 2 and 5 years was 95% (95% CI 88 to 98), 82% (95% CI 72 to 89) and 59% (95% CI 46 to 69), respectively. One secondary malignancy occurred 4.4 years after initial diagnosis in a male subject who received dexrazoxane.

Echocardiographic measures
In total, 227 echocardiograms were quantitated: 85 at baseline (T₀), 85 after completion of doxorubicin therapy (T₁) and 57 1 to 2 years after doxorubicin completion (T₂). At baseline, echocardiographic parameters were notable for preserved SF and systolic strain indices (table 2). Subjects treated with dexrazoxane had slightly lower SF (30.1% vs 33.0%, p=0.025), higher LVDD (p=0.002), worse circumferential strain (p=0.045), higher meridional ESS (p=0.031) and borderline increased circumferential ESS (p=0.064) in comparison with those not treated with dexrazoxane. Other parameters were similar between groups.

The median time from the baseline echocardiogram to completion of doxorubicin therapy was 6.5 months (IQR 4.9 to 7.1), from doxorubicin completion to the T₁ echo-cardiogram was 1.3 months (IQR 0.8 to 2.7) and from doxorubicin completion to the T₂ echocardiogram was 14.7 months (IQR 12.3 to 17.3). Cancer-related death was the most important cause of reduced data points at T₂. Baseline clinical characteristics and available echocardiographic variables were similar for those subjects with and without measurements at T₂ (online supplementary table 1).

Changes in echocardiography measures over time and comparison of dexrazoxane effects in males and females

Unadjusted changes in echocardiographic measures over time are depicted in figures 2 and 3. Propensity-adjusted multivariable linear regression was used to estimate the mean changes in echocardiography measures early after doxorubicin (at T₁) and 1–2 years postdoxorubicin therapy (T₂; data not shown). In males not treated with dexrazoxane (n=15), there was an early increase in LVDS and worsening of circumferential strain. In females not treated with dexrazoxane (n=8), there was evidence of greater dysfunction and worse remodelling, with early and sustained deterioration of SF, circumferential strain and radial strain; increased LVDD, LVDS and meridional ESS; and decreased relative wall thickness. These changes were less pronounced with dexrazoxane treatment. In males treated with dexrazoxane (n=33), slight increases in LVDD and LVDS occurred. In females treated with dexrazoxane (n=29), less pronounced deterioration of SF, circumferential strain and radial strain occurred, in addition to a smaller increase in LVDS.

Using these multivariable regression models, we compared dexrazoxane’s effects according to sex at each time point (tables 3 and 4). In males, dexrazoxane was associated with an attenuation of the deterioration of circumferential strain by 3.4% early after therapy, without significant effects 1–2 years post-therapy. In females, dexrazoxane was associated with an attenuation of the decline in SF (5.7% difference); the increases in LVDD, LVDS and wall stress; and the decreases in relative wall thickness early after therapy, and sustained attenuation of the increases in LVDD and LVDS 1–2 years post-therapy. Overall, females and those not treated with dexrazoxane were more likely to develop increased cavity size and decreased cardiac function.

In tests for interactions between sex and dexrazoxane exposure on the changes in parameters of function and remodelling, there was evidence of effect modification on the changes in SF, LVDD, LVDS and relative wall thickness early after therapy and on LVDD and LVDS 1–2 years post-therapy (all p<0.05). After adjustment for multiple comparisons, the interactions remained significant for the relationships between sex and dexrazoxane.
Table 4  Effect of dexrazoxane on changes in echocardiography measures 1–2 years from baseline after doxorubicin chemotherapy (T2) according to sex

<table>
<thead>
<tr>
<th>Measure</th>
<th>Males (n=29)</th>
<th>Females (n=28)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Effect of dexrazoxane on change at T1 (95% CI)*</td>
<td>Effect of dexrazoxane on change at T1 (95% CI)*</td>
</tr>
<tr>
<td>Shortening fraction (%)</td>
<td>−1.5 (−5.3 to 2.3)</td>
<td>0.43</td>
</tr>
<tr>
<td>LV (cm/BSA0.45)</td>
<td>0.1 (−0.1 to 0.4)</td>
<td>0.42</td>
</tr>
<tr>
<td>LVIDS (cm/BSA0.45)</td>
<td>0.1 (−0.2 to 0.3)</td>
<td>0.65</td>
</tr>
<tr>
<td>Posterior wall thickness (cm/BSA0.45)</td>
<td>0.04 (−0.02 to 0.10)</td>
<td>0.19</td>
</tr>
<tr>
<td>LV mass (g/BSA1.25)</td>
<td>3.4 (−6.2 to 13.0)</td>
<td>0.48</td>
</tr>
<tr>
<td>Relative wall thickness (%)</td>
<td>0.00 (−0.04 to 0.04)</td>
<td>0.90</td>
</tr>
<tr>
<td>Circumferential strain (%)§</td>
<td>0.0 (−3.1 to 3.0)</td>
<td>0.98</td>
</tr>
<tr>
<td>Radial strain (%)</td>
<td>0.9 (−12.7 to 14.4)</td>
<td>0.89</td>
</tr>
<tr>
<td>Meridional ESS (10^3 dynes/cm²)</td>
<td>14.8 (−10.7 to 40.3)</td>
<td>0.25</td>
</tr>
<tr>
<td>Circumferential ESS (10^3 dynes/cm²)</td>
<td>8.9 (−15.1 to 32.8)</td>
<td>0.46</td>
</tr>
</tbody>
</table>

*Difference in the mean change at T2 (1–2 years after doxorubicin therapy completion) between subjects who were exposed and not exposed to dexrazoxane, derived from propensity-adjusted multivariable linear regression.
†P<0.05 for the comparison of mean changes by dexrazoxane exposure, performed separately for males and females.
‡P-values for the interaction between sex and dexrazoxane.
§Increases reflect deterioration of circumferential strain.
BSA, body surface area; ESS, end-systolic stress; LV, left ventricular; LVIDD, LV inner dimension in diastole; LVIDS, LV inner dimension in systole.

on LVIDD (p=0.011) and LVIDS (p<0.001), approached significance for SF (p=0.062) early after therapy, and remained significant for LVIDD (p=0.006) and LVIDS (p<0.001) 1–2 years post-therapy. Overall, these results suggested greater protective effects of dexrazoxane in female children, with similar findings at both time points.

**Relationship between early changes and changes 1–2 years post-doxorubicin**

Finally, we examined the relationship between changes early after doxorubicin (T1) and 1–2 years after doxorubicin (T2). We first compared values at these two time points (online supplementary table 2). Although there was a nonsignificant initial increase in LV mass was noted early after therapy, there was a small but significant reduction in LV mass by 1–2 years post-therapy in relation to this early change. Other changes in cardiac structure and function were sustained, without further deterioration. We also assessed the associations between early changes in cardiac structure and function with changes in SF 1–2 years after doxorubicin completion to identify potential early markers of global systolic dysfunction (table 5). Here, an early 1% deterioration of circumferential or radial strain was associated with SF declines of 0.5% (p=0.010) and 0.1% (p=0.025) at the late time point, respectively. An early 10 g/BSA1.25 increase in LV mass was associated with a decline in SF of 1.2% (p=0.021) at the late time point. These analyses suggest that the early changes in cardiac structure and function persist, and changes in strain and mass may be early markers of dysfunction.

**DISCUSSION**

In this study of children with sarcoma receiving doxorubicin chemotherapy, we report several key findings. First, early after doxorubicin exposure, significant changes in cardiac structure and function occurred in subjects treated with and without dexrazoxane, and these changes persisted 1–2 years post-therapy. Second, greater alterations of cardiac structure and function were found in female children. Third, dexrazoxane mitigated the adverse changes in cardiovascular function and remodelling in both sexes, but protective effects were greater in female children. Fourth, early changes in strain and mass were indicative of late deterioration of SF.

In two recent randomised trials of dexrazoxane cardioprotection with anthracycline therapy in paediatric leukaemia and lymphoma, Lipshultz et al found an improvement in SF with dexrazoxane in females, but...
not males with a significant interaction, and Asselin et al. found significant improvement in SF with dexrazoxane overall.9 10 Our results are additive to these and other studies in adults.16 24 Our data, in conjunction with these recent studies of adults exposed to anthracyclines,16 25 but differs from prior studies in long-term cancer survivors, which demonstrate reductions in LV mass.25 It is possible that myocardial oedema plays a role in these early changes,26 and it is notable that there was a subsequent decrease in mass by the later time point, which may reflect an evolving process.

We acknowledge the potential limitations of our study. A lack of dedicated prospective imaging precluded the ability to assess longitudinal strain or LV ejection fraction, although SF is the most widely used measure in paediatric cardiology. Images were analysed at the archived frame rate of 30 frames per second, which could result in some limitations in strain analyses specifically, although prior studies have demonstrated that this frame rate is adequate for analyses.13 14 Despite our careful adjustments for measured confounders, bias due to unmeasured factors is possible. In addition, although we adjusted for multiple comparisons in our primary interaction analyses, other statistical tests were susceptible to type I error related to multiple comparisons. Sample size and length of follow-up constraints precluded the ability to assess long-term cardiac outcomes with dexrazoxane, including the development of heart failure, oncologic outcomes or mortality. Finally, this study was conducted in a single tertiary care centre, and our results may not be generalisable.

In conclusion, high-dose anthracycline therapy continues to pose a risk of cardiotoxic effects in the post-dexrazoxane era. Female children are more susceptible to these effects and may derive greater cardioprotective benefit from dexrazoxane. These results have potential implications for the care of children receiving anthracyclines.
Heart failure and cardiomyopathies

Author affiliations
1Department of Pediatrics, University of California San Diego School of Medicine, San Diego, California, USA
2Rady Children’s Hospital San Diego, San Diego, California, USA
3Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
4Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
5Department of Pediatrics; Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
6Division of Cardiology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
7Department of Pediatrics; University of California, San Diego, California, USA
8Division of Cardiology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
9Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
10Abramson Cancer Center, Philadelphia, Pennsylvania, USA
11Department of Population Sciences, City of Hope National Medical Center, Duarte, California, USA
12Department of Pediatrics, University of Chicago, Chicago, Illinois, USA
13Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA
14Rady Children’s Hospital San Diego, San Diego, California, USA
15Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
16Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
17Division of Cardiology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
18Department of Population Sciences, City of Hope National Medical Center, Duarte, California, USA
19Department of Pediatrics, University of Chicago, Chicago, Illinois, USA
20Abramson Cancer Center, Philadelphia, Pennsylvania, USA
21Department of Cardiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Contributors HKN: conceptualisation, methodology, data curation, formal analysis, writing-original draft. MEP: methodology, formal analysis, writing-review/editing. NK, AP, RBW and AVD: conceptualisation, methodology, data curation, formal analysis, funding acquisition, writing-review/editing.

Funding This work was supported by the National Institutes of Health (T32-HD060550 [Narayan], R01-HL118018 [Ky]).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES